Nasdaq

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

- 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing ...
Nasdaq

SELLAS Life Sciences Group Reports Positive Overall Survival Data for SLS009 in r/r AML and Updates on Financial Position and Pipeline Developments

SELLAS Life Sciences Group, Inc. announced positive overall survival results from their ongoing Phase 2 trial of SLS009 (tambiciclib) in patients with relapsed/refractory acute myeloid leukemia (AML), ...
Nature

Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival

A number of studies suggest that men with AML treated with intensive chemotherapy have worse survival than women [1,2,3,4,5]. This has been highlighted in a recent perspective [6]. The incidence of ...
ascopubs.org

Racial disparities and survival outcomes in secondary acute myeloid leukemia: A SEER-based analysis.

Venetoclax/azacitidine vs intensive chemotherapy as a bridge to allogeneic HSCT in AML: Experience from Ukraine. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...